Can I read Risankizumab (Skyrizi) on EtoBox?

Risankizumab (Skyrizi) by MUDr. Jiří Horažďovský, Ph.D. is a scholarly article available to read on EtoBox.

What is Risankizumab (Skyrizi) about?

Imunopatogenetic mechanisms of psoriasis extend our possibilities for new targeting therapy. The crucial importance of interleukin 23 (IL-23) was recognized. Risankizumab is the next biologic drug with target inhibition of IL-23. Article summarizes the therapeuric potential of this drug and gives the first clinical experiences by myself.

Author

MUDr. Jiří Horažďovský, Ph.D.

Publisher

Dermatologie pro praxi

Published

2020